Cargando…
ZLM-7 Blocks Breast Cancer Progression by Inhibiting MDM2 via Upregulation of 14-3-3 Sigma
Breast cancer is one of the most prevalent malignancies with poor prognosis. Inhibition of angiogenesis is becoming a valid and evident therapeutic strategy to treat cancer. Recent studies uncovered the antiangiogenic activity of ZLM-7 (a combretastain A-4 derivative), but the regulatory mechanism i...
Autores principales: | Wen, Min, Zou, Zi-Zheng, Luo, Tiao, Li, Xuan, Liu, Su-You, Li, Ji-Jia, Luo, Zhi-Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321038/ https://www.ncbi.nlm.nih.gov/pubmed/35890172 http://dx.doi.org/10.3390/ph15070874 |
Ejemplares similares
-
ZLM-7 inhibits the occurrence and angiogenesis of breast cancer through miR-212-3p/Sp1/VEGFA signal axis
por: Li, Xuan, et al.
Publicado: (2020) -
ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling
por: Su, Min, et al.
Publicado: (2016) -
Draft Genome Sequence of Nafulsella turpanensis ZLM-10(T), a Novel Member of the Family Flammeovirgaceae
por: Zhang, Lei, et al.
Publicado: (2014) -
MDM2 induces EMT via the B-Raf signaling pathway through 14-3-3
por: Ou, Mengting, et al.
Publicado: (2021) -
The Role and Regulatory Mechanism of 14-3-3 Sigma in Human Breast Cancer
por: Ko, SeungSang, et al.
Publicado: (2014)